EEP: Euroespes, S.A. - Summary | Jitta

Euroespes, S.A.

ESP:EEP

Notice
Stock data is unavailable or the company’s delisted.
Price
€0.34
Loss Chance
61.0%
1.96JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (34)
Recent Business Performance (17)
Financial Strength (38)
Return to Shareholders (4)
Competitive Advantage (28)
Jitta Signs
Revenue and EarningEarning loss detected in 2022
Operating MarginDeclined
Recent Business PerformanceEarning decline 451.20% in the last quarter (yoy)
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.96
100.00%
4.64
105.67%
Life Sciences Tools and Services
2.19
100.00%
COMPANY DESCRIPTION
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. The company offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. It also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neuropsychology, digital diagnostics, radiodiagnosis, clinical analysis laboratory, nursing, and cardiology. In addition, the company researches and develops in the fields of biochemistry, health biotechnology, epigenetics, neurosciences, genomics and pharmacogenomics, and nutraceuticals. Euroespes, S.A. was incorporated in 1991 and is headquartered in Corunna, Spain.